Desvenlafaxine Extended-Release Tablets Suppliers & Bulk Manufacturers
Available Forms: Extended-Release Tablets
Available Strengths: 25 mg, 50 mg, 100 mg
Reference Brands: Pristiq®(US & EU), Khedezla®(US)
Category:
Antipsychotropic Drugs
Desvenlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that enhances neurotransmitter levels to help regulate mood and emotional balance. It is primarily used for the treatment of major depressive disorder (MDD) in adults. The extended-release formulation ensures once-daily dosing, providing consistent therapeutic effects with improved adherence and reduced dosing frequency.
Desvenlafaxine Extended-Release Tablets is available in Extended-Release Tablets
and strengths such as 25 mg, 50 mg, 100 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Desvenlafaxine Extended-Release Tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Desvenlafaxine Extended-Release Tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
In the United States, desvenlafaxine extended-release tablets are FDA-approved for the treatment of major depressive disorder (MDD) in adults. As an SNRI, it requires a Boxed Warning regarding the risk of suicidal thoughts and behaviors in young individuals. Regulatory compliance includes GMP manufacturing, bioequivalence studies for generics, and ongoing post-marketing surveillance. Labeling must reflect FDA-approved indications, dosing, and adverse effects.
In the European Union, desvenlafaxine is not widely marketed, but regulatory pathways exist for national or decentralized approval. Applications must include clinical efficacy, pharmacovigilance plans, and Risk Management Plans (RMPs). For compliant global sourcing, visit Pharmatradz.com.
.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing